Back

Jump Trading Takes Stakes in Kalshi and Polymarket for Market-Making

At a glance

  • Jump Trading agreed to acquire minority stakes in Kalshi and Polymarket
  • Equity in Kalshi is fixed; Polymarket stake scales with liquidity provided
  • Kalshi and Polymarket were valued at US$11–15 billion in late 2025

Institutional involvement in prediction markets has increased, with Jump Trading reaching agreements to acquire minority equity positions in both Kalshi and Polymarket in return for providing market-making liquidity.

Jump Trading, a Chicago-based firm recognized for its algorithmic and high-frequency trading strategies, has expanded its participation in prediction markets through these new arrangements. The firm had previously supplied market-making liquidity to Kalshi before the current equity agreements were established.

Under the terms of the agreement with Kalshi, Jump Trading will receive a fixed equity stake. In contrast, the arrangement with Polymarket allows Jump Trading’s equity share to increase in proportion to the amount of trading liquidity it provides in U.S. operations.

These deals reflect a structure where Jump Trading’s involvement is directly linked to its market-making activity, especially for Polymarket, where the equity stake is not fixed but scales with the firm’s trading capacity contribution in the United States.

What the numbers show

  • Polymarket’s valuation was estimated between US$12 billion and US$15 billion in late 2025
  • Kalshi’s valuation was estimated at US$11 billion as of late 2025
  • Jump Trading’s equity in Kalshi is fixed, while its Polymarket stake scales with U.S. liquidity provision

Jump Trading’s history in related sectors includes operating a sports-betting unit on Betfair until 2023. The firm also supported Sporttrade through its venture arm, Jump Capital, indicating ongoing interest in markets that combine financial and predictive elements.

Kalshi and Polymarket have both seen substantial valuations, with estimates placing Kalshi at US$11 billion and Polymarket between US$12 billion and US$15 billion around late 2025. These figures highlight the scale of institutional investment entering the prediction market sector.

The agreements specify that Jump Trading’s stake in Kalshi remains constant, while its equity in Polymarket is determined by the level of trading liquidity it supplies within the United States. This approach aligns Jump Trading’s potential ownership with its operational involvement in the platform.

Through these arrangements, Jump Trading continues to build on its experience in market-making and trading across various platforms, further integrating into the evolving landscape of prediction markets.

* This article is based on publicly available information at the time of writing.

Related Articles

  1. On February 2, 2026, SpaceX acquired xAI, forming a $1.25 trillion tech group that merges space and AI capabilities, according to company statements.

  2. AI-assisted romance novels now account for 12% of Kindle Unlimited releases, while 19% of U.S. adults have interacted with AI companions.

  3. Updates for Pantheon’s itemization and economy include a player market and mail system set for 2026, according to the developers' roadmap.

  4. Ninety-five percent of top English councils report deficits due to rising costs for special educational needs, according to published data.

  5. A statement outlines plans for euro adoption and a progressive tax system, including a one-percent wealth tax on high assets, according to reports.

More on Business

  1. Over 300 employees were laid off at The Washington Post, with Will Lewis resigning as CEO. Jeff D’Onofrio is now interim CEO, according to reports.

  2. Kering's Q4 2025 sales fell 3% to €3.91 billion, less than expected. Shares rose over 15% as CEO Luca de Meo targets growth for 2026.

  3. In early 2025, young entrepreneurs in San Francisco raised over $50 billion for AI startups, fueling a significant tech boom, according to reports.

  4. Food fraud affects up to 10% of retail products, costing the US $15 billion annually, with olive oil, honey, and coffee frequently targeted.

  5. A multi-year agreement focuses on oncology and gastrointestinal drug programs, according to reports. Iambic may receive over $1.7 billion.